AB Science reports a new publication in the scientific journal PLOS One
15/05/2025 – AB Science today reports a new publication in the scientific journal PLOS One, showing promising neuroprotective effects of masitinib
CNews – Interview of Alain Moussy
Alain Moussy is interviewed by Sophie de Menthon in the show “Patrons en Question”.
Annual financial results as of 31 December, 2024
12/05/2025 – AB Science reports its revenues for the year 2024 and provides an update on its activities
AB Science will present new data from masitinib clinical program in ALS in two presentations at the 2025 ENCALS Annual Meeting
05/05/2025 – AB Science announced that new analyses from its phase 3 trial in ALS and preclinical animal model data have been accepted for presentation at the ENCALS annual meeting (June 3-6, 2025, Turin, Italy)
AB Science will publish its 2024 annual financial report on May 9, 2025
01/05/2025 – AB Science today announced that it has postponed the publication of its 2024 annual financial report, initially scheduled for 30 April 2025, to give the auditors time to complete their audit work
European Medicines Agency has granted orphan drug designation in the European Union for AB8939 in the treatment of acute myeloid leukemia
23/04/2025 – AB Science announces today that the European Medicines Agency (EMA) Committee for Orphan Medicinal Products (COMP) granted orphan drug status to AB8939 for the treatment of acute myeloid leukemia (AML)
AB Science receives notice of allowance for Unites States patent covering masitinib until 2040 in the treatment of sickle cell disease
14/04/2025 – AB Science today announced that the United States Patent Office has issued a Notice of Allowance for a patent relating to methods of treating sickle cell disease with its lead compound masitinib, based on preclinical data
Article from the leading publication Life Sciences Magazine featuring AB Science’s masitinib and its Phase 3 principal investigator, the neurologist Patrick Vermersch
04/03/2025 – AB Science today announces that The Life Sciences Magazine, a leading publication in the fields of healthcare and medical advancements, has featured an exclusive cover story on Professor Patrick Vermersch, principal investigator of phase 3 confirmatory study with masitinib in progressive forms of multiple sclerosis
Summary of the webcast held on January 28, 2025
29/01/2025 – AB Science provides a summary of the webcast held on January 28, 2025
AB Science webcast of January 28, 2025
28/01/2025 – Presentation of the AB Science webcast held on January 28, 2025